Last reviewed 2026-04-20 · How we verify

panHer

Bristol-Myers Squibb · Phase 1 active Small molecule Quality 3/100

At a glance

Generic name	panHer
Also known as	BMS-599626
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin (PHASE1)
Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer (PHASE2)
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer (PHASE1)
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC (PHASE2)
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors (PHASE1)
BMS-599626 in Patients With Advanced Solid Malignancies (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results